That is necessary, because the way a protein in the human body folds figures out if a pharmaceutical will have the ability to bind to that protein and work. Simply put, we need to know how these proteins fold if we desire a drug to work. Historically, this has been a trial-and-error procedure (brownstone research). And now, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it a lot easier to develop drugs that do what they're developed to do. This was an advancement practically no one saw. But it's going to have extensive ramifications for treating illness. I predict that Alpha, Fold will be 98% precise by the end of 2021.
And, of course, there will be plenty of investment opportunities in this space, too. Moving subjects It's going to be a good year for bitcoin. I'm bullish on it in 2021 (jeff brown genetic sequencer stock). That stated, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I would not be shocked if it drew back possibly significantly prior to going greater - tech predictions. I have actually been covering bitcoin for a very long time now. One of the first research study reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial recommendation, I titled my report "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time. We were mainly educating readers. But that's not the huge concern anymore. Now we're seeing institutional cash lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche business. Mass, Mutual is a relied on 170-year-old organization. So think of that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a huge reason I'm bullish on it this year. jeff brown tech stock 2021. Regards, Jeff Brown, Editor, The Bleeding Edge I have a perk forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I predict 2021 will be another record year in IPOs. There are many fantastic personal companies on the verge of hitting the public markets And I have actually been working on a brand-new method for you to invest even prior to these companies go public.
This opportunity has actually been building over the last few years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover out all the information. Go right here to reserve your area for totally free.
Emma Walsh here, managing editor of the Journal. Regular Journal readers know that tech isn't our normal beat (bleeding edge). And when it comes to tech investing, we leave it to the specialists. Fortunately, we have a number of such professionals in our Rolodex. Our associate Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing professionals we understand (jeff brown stock market prediction). In truth, he had a number of triple-digit returns in his Brownstone Research portfolios in 2015. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to have a look at the big photo and predict what's simply around the corner.
That includes things like 5G networks, biotech, expert system, and a lot more. These trends are experiencing rapid growth and creating incredible chances for financiers. I wish to make certain all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see being available in the next 12 months Our new 5G (fifth-generation) cordless networks are a topic I've been covering for years now. jeff brown genetic sequencing stock. But in spite of what many readers might believe, this is a pattern that's just beginning. Although the COVID-19 pandemic interrupted supply chains in 2015, an outstanding 250 million 5G-enabled gadgets were still sold.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (jeff brown genetic sequencing stock). Losing two months of manufacturing and sales actually affects the number of 5G gadgets are offered in the calendar year. When you consider all of that, selling 250 million units is impressive. More importantly, the hold-ups brought on by the pandemic produced a ton of bottled-up demand. And that demand is now going to be pushed into 2021. In reality, I forecast that more than 500 million 5G gadgets will be delivered in 2021 - jeff brown genetic sequencer stock. And that's not my only 5G prediction When I've discussed 5G in the past, I've described its 3 different phases.
In Stage Two, 5G devices go on sale. 5G phones and other items begin to reach customers. And in Stage Three, 5G services start to be used (future report). That's when we start to see applications working on 5G networks. Consider things like massive multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my 2nd 5G forecast for 2021 is that we will start Phase Three by this summer season. This begins something of a virtuous cycle: The majority of people don't truly appreciate the innovation. But they will care if there are amazing applications that can only be accessed with a 5G phone.
That results in more 5G apps being developed. In reality, 5G is going to open a suite of extraordinary applications: self-driving vehicles, the Internet of Things, robotic surgery, and more. All of these technologies need 5G. The investment opportunities moving forward will be huge. Stepping far from 5G, the next crucial innovation I anticipate in 2021 is CRISPR hereditary editing. CRISPR stands for "clustered frequently interspaced short palindromic repeat." It's a mouthful. But it is among the most amazing developments in biotechnology. At a high level, CRISPR is an innovation that can modify our genetic makeup as if it were software application.
The program can crash or not operate properly. CRISPR uses a similar concept but with our genetic code. "Typos" in our genome can result in illness. CRISPR can correct these "typos." For many years, CRISPR was mostly a specific niche technology that wasn't well comprehended. And during that time, there were actually just three business operating in this space. But things are changing. CRISPR is no longer just theoretical. We're seeing actual results. We're treating diseases and seeing that this innovation just works. And as a result, a "second crop" of early-stage CRISPR business is going public and providing amazing returns. This whole market is effectively a greenfield opportunity.
There's space for many companies to exist in this space. jeff brown genome sequencing stock. And there will be more. That's my forecast for CRISPR in 2021. I predict that 2 or 3 more genetic editing companies will hold their IPOs. Sticking to biotechnology, we are seeing fantastic things taking place at the merging of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its newest Alpha, Fold software can precisely forecast the folding of a protein based entirely on its amino acid sequence with 92. 4% precision. That's important since the method a protein in the body folds figures out if a pharmaceutical will have the ability to bind to that protein and work.
Historically, this has actually been an experimental process. However now, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it a lot easier to create drugs that do what they're designed to do. And here's my next prediction. I forecast that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one however a number of drug therapies produced using this technology. This was among those breakthroughs that nearly no one saw. However it's going to have extensive implications for curing illness. And, obviously, there will be a lot of investment chances in this area, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be shocked if it pulled back maybe significantly before going higher. I've been covering bitcoin for a long period of time now. One of the first research study reports I ever published was on bitcoin - jeff brown 2021 stock picks. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anybody who followed my suggestion. But at the time of that preliminary recommendation, I titled my report, "What's the Big Deal With Bitcoin?" That shows you where the conversation was at the time.
However nobody is asking that question any longer. Now, we're seeing institutional money lastly taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. korean actress. Mass, Mutual is a 150-year-old organization. So think about that. In 5 years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another reward forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the details is up to date since February 2021, but we could not individually verify this claim. Given Jeff Brown's past, he likely has a substantial net worth, but we can't hammer down an exact figure at this moment. Brown is best understood for his sage-like ability to pick winning technology stocks. He invested more than 25 years looking into technology business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience offers him an excellent point of view on the market. He's always on the hunt for brand-new opportunities, and he shares much of his finest picks in the Future Report.
That's full marks, but it's not ridiculously reasoned. Brown has an exceptional track record as a stock-picker, and he successfully predicted a few of the greatest economic events of the past 20 years. Although he doesn't appear to launch his choices to the public, the service's success is a direct indicator of Brown's stock-picking expertise. Nobody on Wall Street gets it best whenever, but Jeff Brown's accurate predictions have earned him legions of dedicated followers. That states a lot about his capability. The Near Future Report is released by Brownstone Research study, a popular financial research study publisher. Brownstone Research offers numerous research study services with a wide range of specializations - jeff brown biotech pick.
The company is also affiliated with Bonner & Partners, another well-respected research publisher - biotech stock. On its site, Brownstone states its mission is to supply retail investors with professional-grade research study: "For too long, the best investment research study has actually not been offered to specific investors. It has been typically reserved for investment banks, hedge funds, personal equity, and high-net-worth clients. jeff brown stock market prediction. The objective of Brownstone Research study is to make that kind of exclusive research offered to any financiers looking to get an edge in the markets. The goal is basic to deliver special and profitable financial investment research study discovered nowhere else." -Brownstone Research study website excerpt from the Jeff Brown is the creator of Brownstone Research study, and he also functions as the company's Chief Financial investment Expert.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to provide its clients. After years of constant success at the helm of top-tier business like Tesla and Area, X, Elon Musk is a home name throughout the majority of America. If you understand even a little bit about the marketplace, you know that he has a reputation as a King Midas of sorts. future report. Whatever he touches relies on gold! Jeff is well mindful of Elon Musk's executive expertise, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge task.
In truth, Brown thinks S.A.V. biotech stock. might be "the most significant trend of the 2020s, and he's not alone. Examine out these quotes from other widely known S.A.V. bulls: Elon's next huge act will be weding two cutting-edge technologies: artificial intelligence and electrical automobiles. Musk hopes the combination will help him establish the first fully-autonomous, self-driving cars ever. It's nothing short of the automotive market's Holy Grail. As you know, electric cars and self-driving cars and truck stocks have actually been huge this year, however the Wall Street maker has actually been huge on hype without much concrete result. In spite of a drastic increase in competitors over the past few years, Brown still thinks Musk has the very best chance of putting everything together.
tech could be the magic string that connects all of it together. S.A.V. stands for Shared Autonomous Vehicle, and it could be the future of transportation. Generally, this technology would allow you to lease out your cars and truck as an autonomous, self-driving taxi when you're not using it. You simply leave the automobile and press a button on an app that informs the automobile to "sign up with the fleet." Next thing you understand, you're unwinding on your sofa while your vehicle shuttles ride-sharers around town. Best of all, you get to keep a hefty chunk of the revenues. It sounds crazy, but it might be closed than you believe.